Skip to content
OpenCapital
Get started

Opko Health OPK Convertible Debt (Non-Current)

Convertible Debt (Non-Current) at other companies

ALN
Alnylam PharmaceuticalsALNY
——

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.14B+11.5%
P/S2×+0.5×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0×0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:ConvertibleLongTermNotesPayable.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's convertible debt (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's convertible debt (non-current)?
Opko Health (OPK) reported convertible debt (non-current) of $87.38M in Q1 2026.
How has Opko Health's convertible debt (non-current) changed year-over-year?
Opko Health's convertible debt (non-current) increased by 13.1% year-over-year, from $77.23M to $87.38M.
What is the long-term trend for Opko Health's convertible debt (non-current)?
Over 5 years (2020 to 2025), Opko Health's convertible debt (non-current) has grown at a -17.5% compound annual growth rate (CAGR), from $221.99M to $85.02M.
What does convertible debt (non-current) mean?
This represents the principal amount of debt that can be converted into equity and is due for repayment beyond a one-year timeframe. It reflects the company's long-term capital structure and its strategy for financing growth through hybrid instruments. This metric is essential for assessing long-term solvency and the potential for long-term equity dilution.